Novo Nordisk India teamed up with Emcure Pharma to launch Poviztra (semaglutide injection 2.4 mg), a second brand of Wegovy, in India. The collaboration aims to broaden access to effective obesity treatment across the country, particularly through pharmacies and regions beyond Novo Nordisk India’s current reach.
Poviztra: Indication and Benefits
Poviztra, like Wegovy, is indicated for:
*Chronic weight management
*Reduction in the risk of major adverse cardiovascular events in individuals with overweight or obesity
It supports a reduced-calorie diet and increased physical activity, helping patients achieve sustainable weight loss and improved health outcomes.
Strengthening Distribution and Reach
The partnership allows Emcure Pharma to become the first Indian company with exclusive rights to distribute and commercialize Poviztra. By leveraging Emcure’s extensive marketing capabilities and deep understanding of India’s diverse geographical landscape, the collaboration ensures that semaglutide reaches patients who need it most. Satish Mehta, CEO and Managing Director of Emcure Pharma, stated, “We believe in the potential of semaglutide. With our strong understanding of India and established marketing capabilities, we are confident about making this molecule available to patients who need it the most.”
Addressing the Obesity Challenge in India
Obesity is a serious chronic disease affecting millions of people across India, leading to significant unmet medical needs. Jay Thyagarajan, Senior Vice President, Region APAC, Novo Nordisk, said, “Recognising the magnitude of the obesity challenge, we launched Wegovy in India a few months ago. Now, we are happy to join hands with Emcure Pharma to broaden access to high-quality, safe, and effective obesity treatment.”
Making Semaglutide Accessible
The collaboration is part of Novo Nordisk’s ongoing efforts to make its innovative semaglutide molecule more accessible. It aims to reach a greater number of people living with overweight and obesity in India. MSN.com reported that the partnership combines Novo Nordisk’s expertise in obesity treatment with Emcure’s local reach and marketing strength. Together, they aim to expand Poviztra’s availability and improve health outcomes nationwide.
